Entering text into the input field will update the search result below
Join now
Search for Symbols, analysts, keywords
Log in
STML
Stemline Therapeutics, Inc.
Stock Price & Overview
Follow
STML is defunct since March 10, 2019.
Summary
All
Analysis
Comments
News
Transcripts
SEC Filings
Related Analysis
Analysis
See All Analysis »
News
Latest Headlines
All
Articles
News
European advisory group backs Stemline's Elzonris for rare blood cancer
European advisory group thumbs down on Stemline's Elzonris
Stemline Therapeutics acquired by Menarini Group
Stemline rockets 151% premarket on Menarini bid
Stemline Therapeutics (STML) Investor Presentation - Slideshow
Stemline Therapeutics, Inc. (STML) CEO Ivan Bergstein on Q4 2019 Results - Earnings Call Transcript
Stemline Therapeutics EPS misses by $0.03, revenue in-line
Stemline Therapeutics: Down, But Not Out
Stemline Therapeutics (STML) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow
Stemline Therapeutics sees Elzonris Q4 revenues of $11.8M
More News And Analysis »
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
